Results 141 to 150 of about 843,559 (297)
Figure 1 Patient selection flowchart. CCRT, concurrent chemoradiotherapy; NCCRT, nimotuzumab and concurrent chemoradiotherapy. Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) harboring high‐risk pathological features after radical surgery face high recurrence rates.
Yuejia Zhou +8 more
wiley +1 more source
Humanized Anti-Trop-2 Monocolonal Antibodies and Uses Thereof
The present invention relates to humanized anti-Trop-5 2 monoclonal antibodies and their fragments, derivatives and conjugates. In particular the present invention relates to monoclonal antibodies consisting of sequences of human and murine mixed ...
Alberti Saverio, Emanuela Guerra
core
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani +5 more
wiley +1 more source
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu +12 more
wiley +1 more source
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou +4 more
wiley +1 more source
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando +17 more
wiley +1 more source
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu +4 more
wiley +1 more source
This study reports exploratory and predominantly post hoc subgroup analyses, according to baseline eosinophil count and FeNO levels. In adults with moderate‐to‐severe uncontrolled asthma, rademikibart produced rapid and sustained improvements in lung function and asthma control.
Michael E. Wechsler +3 more
wiley +1 more source
Advanced IBD therapies appear safe and effective in PSC‐IBD. However remission and response rates appear numerically attenuated compared to IBD‐only populations. Created in BioRender (https://BioRender.com/h9bxgij). ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD)
Amera Elzubeir +6 more
wiley +1 more source
Protective role of Galectin‐3 in prion disease through regulation of microglial PrPSc uptake
Galectin‐3 (Gal3) is induced in reactive microglia during prion disease and promotes microglial uptake of PrPSc. Gal3 deficiency reduces prion sequestration and accelerates disease progression, revealing a protective role for Gal3. Abstract Microglia constitute a major innate defense mechanism against prion infection; however, the molecular pathways ...
Natallia Makarava +8 more
wiley +1 more source

